A national survey of four decades of hereditary angioedema prophylaxis: Efficacy and safety of old and new drugs
Authors:
Open Access
- 11 June 2025
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 279, 110542
Abstract
No abstract availableKeywords
Funding Information
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
- Kulturális és Innovációs Minisztérium (EK\u00D6P-2024-31)
This publication has 63 references indexed in Scilit:
- Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic ReviewClinical Reviews in Allergy & Immunology, 2024
- Subcutaneous C1‐Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1‐INH‐HAEClinical Case Reports, 2021
- Lanadelumab: First Global ApprovalDrugs, 2018
- Thyroid hormones and complement parameters in hereditary angioedema with C1-inhibitor deficiencyAnnals of Allergy, Asthma & Immunology, 2016
- The Story of Angioedema: from Quincke to BradykininClinical Reviews in Allergy & Immunology, 2016
- Critical appraisal of androgen use in hereditary angioedema: a systematic reviewAnnals of Allergy, Asthma & Immunology, 2015
- Danazol-Induced Hepatocellular Carcinoma in a Patient with Hereditary AngioedemaJournal of Gastrointestinal Cancer, 2012
- The effect of long-term danazol prophylaxis on liver function in hereditary angioedema—a longitudinal studyEuropean Journal of Clinical Pharmacology, 2009
- Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patientsAtherosclerosis, 2008
- Clinical and biochemical effects of stanozolol therapy for hereditary angioedemaJournal of Allergy and Clinical Immunology, 1981